Iodine and differentiated thyroid cancer: Pathogenetic and therapeutic implications

Hormones

Volumn 8, Issue 3, 2009, Pages 192-198

  Smyth, Peter P A ^a   Cloughley, G C ^a   Clarke, C ^a   Smith, D F ^a   Burbridge, E ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Iodine; Iodine deficiency; Radioiodine therapy; Seaweed; Thyroid cancer

Indexed keywords

IODINE; IODINE 125; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR LAMBDA; RADIOACTIVE IODINE; RAS PROTEIN; THYROTROPIN; TRANSCRIPTION FACTOR PAX8; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DIETARY INTAKE; HUMAN; INGESTION; MUTATION; NUTRITION; PATHOGENESIS; PREVALENCE; SEAWEED; THYROID CANCER; THYROID FOLLICLE CELL; METABOLISM; PAPILLARY CARCINOMA; REVIEW; THYROID TUMOR;

CARCINOMA, PAPILLARY; HUMANS; IODINE; IODINE RADIOISOTOPES; SEAWEED; THYROID NEOPLASMS;

EID: 70349237564     PISSN: 11093099     EISSN: None     Source Type: Journal    
DOI: 10.14310/horm.2002.1235     Document Type: Conference Paper

References (48)

1. Feldt-Rasmussen U, 2001 Iodine and cancer. Thyroid 11: 483-486.
2. Burgess JR, 2002 Temporal trends for thyroid carcinoma in Australia: an increasing incidence of papillary thyroid carcinoma (1982-1997). Thyroid 12: 141-149.
3. Knobel M, Medeiros-Neto G, 2007 Relevance of iodine intake as a reputed predisposing factor for thyroid cancer. Arq Bras Endocrinol Metabol 51: 701-712.
4. Robbins J, Schneider AB, 2000 Thyroid cancer following exposure to radioactive iodine. Rev Endocr Metab Disord. 3: 197-203.
5. Nakazawa T, Kondo T, Kobayashi Y, et al, 2005 RET gene rearrangements (RET/PTC1 and RET/PTC3) in papillary thyroid carcinomas from an iodine-rich country (Japan).Cancer 104: 943-951
6. Nikiforova MN, Nikiforov YE, 2008 Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 8: 83-95.
7. Robbins J, Dunn JT, Bouville A, et al, 2001 Iodine nutrition and the risk from radioactive iodine: a workshop report in the Chernobyl long-term follow-up study. Thyroid. 11: 487-491. (Pubitemid 32494597)
8. Belfiore A, La Rosa GL, La Porta GA, et al, 1992 Cancer risk in patients with cold thyroid nodules: relevance of iodine intake, sex, age, and multinodularity. Am J Med 93: 363-369.
9. Williams ED, Doniach I, Bjarnason O, Michie W, 1977 Thyroid cancer in an iodide rich area: a histopathological study. Cancer 39: 215-222. (Pubitemid 8029001)
10. Franssila K, Saxén E, Teppo L, et al, 1981 Incidence of different morphological types of thyroid cancer in the Nordic countries. Acta Pathol Microbiol Scand 89: 49-55. (Pubitemid 11188900)
11. Goodman MT, Yoshizawa CN, Kolonel LN, 1988 Descriptive epidemiology of thyroid cancer in Hawaii. Cancer 61: 1272-1281.
12. Wolff J, 1989 Excess iodide inhibits the thyroid by multiple mechanisms. Adv Exp Med Biol 261: 211-264.
13. Kasagi K, 2007 Epidemiology of thyroid tumors: effect of environmental iodine intake. Nippon Rinsho 65: 1953-1958.
14. Harach HR, Escalante DA, Onativia A, Lederer Outes J, Saravia Day E, Williams ED, 1985 A study on the relationship between solid cell nests and mucoepidermoid carcinoma of the thyroid. Histopathology 9: 195-207. (Pubitemid 15136724)
15. Langsteger W, Költringer P, Wolf G, et al, 1993 The impact of geographical, clinical, dietary and radiation- induced features in epidemiology of thyroid cancer. Eur J Cancer 29: 1547-1553. (Pubitemid 23251795)
16. Reynolds RM, Weir J, Stockton DL, Brewster DH, Sandeep TC, Strachan MW, 2005 Changing trends in incidence and mortality of thyroid cancer in Scotland. Clin Endocrinol(Oxf) 62: 156-162. (Pubitemid 40203909)
17. Belfiore A, La Rosa GL, Padova G, Sava L, Ippolito O, Vigneri R, 1987 The frequency of cold thyroid nodules and thyroid malignancies in patients from an iodine- deficient area. Cancer 60: 3096-3102 (Pubitemid 18005890)
18. Leenhardt L, Grosclaude P, Chérié-Challine L, Thyroid Cancer Committee, 2004 Increased incidence of thyroid carcinoma in France: a true edipemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 14: 1056-1060. (Pubitemid 40076130)
19. Burgess JR, Tucker P, 2006 Incidence trends for papillary thyroid carcinoma and their correlation with thyroid surgery and thyroid fine-needle aspirate cytology. Thyroid 16: 47-53. (Pubitemid 43346503)
20. Burgess JR, Dwyer T, McArdle K, Tucker P, Shugg D 2000 The changing incidence and spectrum of thyroid carcinoma in Tasmania (1978-1998) during a transition from iodine sufficiency to iodine deficiency. J Clin Endocrinol Metab 85: 1513-1517. (Pubitemid 32289493)
21. Vitale,M, di Matola T, D'Ascoli F, et al, 2000 Iodide excess induces apoptosis in thyroid cells through a p53-independent mechanism involving oxidative stress. Endocrinology 141: 598-605. (Pubitemid 32250483)
22. Venturi S, Donati FM, Venturi A, Venturi M, Grossi L, Guidi A, 2000 Role of iodine in evolution and carcinogenesis of thyroid, breast and stomach. Adv Clin Path 4: 11-17.
23. Mutaku JF, Poma JF, Many MC, Denef JF, van Den Hove MF, 2002 Cell necrosis and apoptosis are differentially regulated during goitre development and iodine-induced involution. J Endocrinol 172: 375-386.
24. Gärtner R, Dugrillon A, Bechtner G, 1996 Evidence that iodolactones are the mediators of growth inhibition by iodine on the thyroid. Acta Med Austriaca 23: 47-51. (Pubitemid 126443906)
25. Dugrillon A, 1996 Iodolactones and iodoaldehydes- mediators of iodine in thyroid autoregulation. Exp Clin Endocrinol Diabetes 104: Suppl 4: 41-45. (Pubitemid 26418398)
26. García-Solis P, Alfaro Y, Anguiano B, et al, 2005 Inhibition of N-methyl-N-nitrosourea-induced mammary carcinogenesis by molecular iodine (12) but not by iodide (I-) treatment Evidence that 12 prevents cancer promotion. Mol Cell Endocrinol 236: 49-57.
27. Smyth PP, 2003 Role of iodine in antioxidant defence in thyroid and breast disease. Biofactors 19: 121-130.
28. Joanta AE, Filip A, Clichici S, Andrei S, Daicoviciu D, 2006 Iodide excess exerts oxidative stress in some target tissues of the thyroid hormones. Acta Physiol Hung 93: 347-359.
29. Hay ID, Thompson GB, Grant CS, et al, 2002 Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 26: 879-885.
30. Dohán O, De la Vieja A, Paroder V, et al, 2003 The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance. Endocr Rev 24: 48-77.
31. Riesco-Eizaguirre G, Santisteban P, 2006 A perspective view of sodium iodide symporter research and its clinical implications. Eur J Endocrinol 155: 495-512. (Pubitemid 44608424)
32. Spitzweg C, Morris JC, 2002 Sodium Iodide Symporter (NIS) and Thyroid. Hormones (Athens) 1: 22-34.
33. Kogai T, Taki K, Brent GA, 2006 Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr Relat Cancer 13: 797-826. (Pubitemid 44763258)
34. Boelaert K, Smith VE, Stratford AL, 2007 PTTG and PBF repress the human sodium iodide symporter. Oncogene 26: 4344-4356. (Pubitemid 47014460)
35. Schmutzler C, Winzer R, Meissner-Weigl J, Köhrle J, 1997 Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in non- transformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun 240: 832-838. (Pubitemid 28271806)
36. Park JW, Zarnegar R, Kanauchi H, et al, 2005 Troglitazone, the peroxisome proliferator-activated receptor- gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid 15: 222-231. (Pubitemid 40418689)
37. Venkataraman GM, Yatin M, Marcinek R, Ain KB, 1999 Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I-symporter gene methylation status. J Clin Endocrinol Metab 84: 2449-2457. (Pubitemid 30670879)
38. Kitazono M, Robey R, Zhan Z, et al, 2001 Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 86: 3430-3435. (Pubitemid 32673517)
39. Zarnegar R, Brunaud L, Kanauchi H, et al, 2001 Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor. Surgery 132: 984-990.
40. Clarke C, Burbridge E, Smyth PPA, 2004 Deacetylating agents as mediators of iodide uptake and efflux in thyroid and breast. Endocrine Abstracts 7: P81.
41. Hou X, Yan X, Chai C, 2000 Chemical Species of iodine in some seaweeds II. Iodine-bound biological macromolecules. J Radioanal Nucl Chem 245: 461-467.
42. Kupper FC, Schweigert N, et al, 1998 Iodine Uptake. In Laminariales Involves Extracellular, Haloperoxidase- Mediated Oxidation of Iodide. Planta 207: 163-171.
43. Smyth Peter 2006 Seaweed. Iodine and Health (2006) SOLAS-Ireland 1st National Report., Ed. C.D. O'Dowd, ISBN 978-0-9553862-1-3 [0-9553862-1-7]
44. Dohán O, Portulano C, Basquin C, Reyna-Neyra A, Amzel LM, Carrasco N, 2007 The Na+/I symporter (NIS) mediates electroneutral active transport of the environmental pollutant Perchlorate. Proc Natl Acad Sci USA 104: 20250-20255.
45. Markou K, Georgopoulos N, Kyriazopoulou V, Vagenakis AG, 2001 Iodine-Induced hypothyroidism. Thyroid 11: 501-510.
46. Bogazzi F, Bartalena L, Pinchera A, Martino E, 2002 Adjuvant effect of lithium on radioiodine treatment of hyperthyroidism. Thyroid 12: 1153-1154. (Pubitemid 36114825)
47. Morrissey J, Kraan S, Guiry MD, 2001 A guide to commercially important seaweeds on the Irish coast. Bord Iascaigh Mhara 66: www.bim.ie
48. Teas J, Pino S, Critchley A, Braverman LE, 2004 Variability of iodine content in common commercially available edible seaweeds. Thyroid 14: 836-841. (Pubitemid 39489926)